Cargando…

Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin

OBJECTIVE: The aim of this study was to investigate whether a new generic rosuvastatin is non-inferior to a proprietary one in terms of lipid-lowering efficacy. We also evaluated its non-lipid effects including adverse events. METHODS: One-hundred and fifty-eight patients with cardiovascular risks r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyoeun, Lee, Chan Joo, Choi, Donghoon, Kim, Byeong-Keuk, Kim, In-Cheol, Kim, Jung-Sun, Ahn, Chul-Min, Hong, Geu-Ru, Cho, In-Jeong, Shim, Chi-Young, Lee, Sang-Hak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Lipidology and Atherosclerosis 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379087/ https://www.ncbi.nlm.nih.gov/pubmed/32821737 http://dx.doi.org/10.12997/jla.2020.9.2.283

Ejemplares similares

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)
por: Park, Jin-Sun, et al.
Publicado: (2016)

Effect and Safety of Rosuvastatin in Acute Ischemic Stroke
por: Heo, Ji Hoe, et al.
Publicado: (2016)

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study
por: Lee, Jiwoo, et al.
Publicado: (2020)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial
por: Lee, Yong-Joon, et al.
Publicado: (2023)

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2017)

The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa
por: de Jager, Henk, et al.
Publicado: (2018)

Efficacy and safety of co‐administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia
por: Jin, Xuan, et al.
Publicado: (2020)

Current Perspectives on rosuvastatin
por: Hu, Miao, et al.
Publicado: (2013)

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo
por: Cho, Yongin, et al.
Publicado: (2020)

Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome
por: Jung, Lae-Young, et al.
Publicado: (2016)

Factors of Compliance in Patients with Hypercholesterolemia Using Rosuvastatin in Primary Care
por: Kim, Hye Young, et al.
Publicado: (2012)

Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia
por: Rhee, Moo-Yong, et al.
Publicado: (2020)

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients
por: Saeedi, Ramesh, et al.
Publicado: (2015)

Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
por: Jang, Ji-Yong, et al.
Publicado: (2015)

Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers
por: Yoon, Deok Yong, et al.
Publicado: (2020)

Rosuvastatin and chronic hepatitis C
por: Yoshida, Eric M.
Publicado: (2011)

Rosuvastatin induced photolocalized purpura
por: Thabouti, Marwa, et al.
Publicado: (2022)

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction
por: Ren, Yizhi, et al.
Publicado: (2017)

Erratum to: Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients
por: Jang, Ji-Yong, et al.
Publicado: (2015)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin
por: Kim, Se Yong, et al.
Publicado: (2015)

A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia
por: Kim, Min Chul, et al.
Publicado: (2023)

Effect of Rosuvastatin on Bovine Pericardial Aortic Tissue Valve Calcification in a Rat Subdermal Implantation Model
por: Lee, Seung Hyun, et al.
Publicado: (2017)

Co-administration of ursodeoxycholic acid with rosuvastatin/ezetimibe in a non-alcoholic fatty liver disease model
por: Seo, Sang Hyun, et al.
Publicado: (2022)

Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects
por: Kim, Yun, et al.
Publicado: (2019)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
por: Gandhi, Sanjay K, et al.
Publicado: (2012)

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
por: Han, Eugene, et al.
Publicado: (2017)

Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients at Cardiovascular Risk
por: Yang, Yujin, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Efficacy and safety of rosuvastatin in the management of dyslipidemia
por: Rubba, Paolo, et al.
Publicado: (2009)

Preparation and optimization of microemulsion of rosuvastatin calcium
por: Patel, Zalak B., et al.
Publicado: (2012)

Rosuvastatin-Induced Acute Interstitial Nephritis
por: Londrino, Francesco, et al.
Publicado: (2013)

The influence of the intestinal microflora to the efficacy of Rosuvastatin
por: Wang, Lijun, et al.
Publicado: (2018)

Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans
por: Bae, Soo Hyeon, et al.
Publicado: (2018)

Rosuvastatin Prevents the Exacerbation of Atherosclerosis in Ligature-Induced Periodontal Disease Mouse Model
por: Suh, Jin Sook, et al.
Publicado: (2020)

Effect of High-Intensity Rosuvastatin vs. Combination of Low-Intensity Rosuvastatin and Ezetimibe on HbA1c Levels in Patients without Diabetes: A Randomized IDEAL Trial
por: Choe, Jeongcheon, et al.
Publicado: (2023)

Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers
por: Kim, Tae-Eun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ij4sc3pgvjhvvtdbl8pqej3ud7